
Opinion|Videos|June 11, 2024
ADRIATIC: Durvalumab as Consolidation Treatment for Limited-Stage SCLC
Joshua K. Sabari, MD, and the Oncology Brothers discuss recent findings from the ADRIATIC study focused on durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.

Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.

FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.

Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.

Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
2
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
3
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
4
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
5
